Ben Zimmer, Priovant CEO

Roivant un­veils lat­est spin­out as Pfiz­er en­trusts JAK1/TYK2 to Pri­o­vant

In No­vem­ber, Pfiz­er dis­closed it’s spun out the Phase II dual JAK1/TYK2 in­hibitor to a start­up formed in col­lab­o­ra­tion with an un­named, ex­pe­ri­enced part­ner.

We now know who the part­ner is. And as Pfiz­er and Roivant of­fi­cial­ly take the wraps off Pri­o­vant Ther­a­peu­tics, the com­pa­nies re­veal that they have start­ed two reg­is­tra­tional tri­als of the drug, bre­poc­i­tinib, as part of a broad­er plan to de­vel­op a big, first-in-class fran­chise span­ning mul­ti­ple or­phan and spe­cial­ty au­toim­mune dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.